Showing 1811-1820 of 2105 results for "".
- Favorable Results for Radiprodil Tx for GRIN Disorders Leads to Launch of Study to Test Treatment in Those with Tuberous Sclerosis or Focal Cortical Dysplasiahttps://practicalneurology.com/news/favorable-results-for-radiprodil-tx-for-grin-disorders-leads-to-launch-of-study-to-test-treatment-in-those-with-tuberous-sclerosis-or-focal-cortical-dysplasia/2470617/Treatment with radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), was well tolerated and associated with a significant reduction in seizure frequency in children with GRIN-related neurod
- Alzheimer's Drug Discovery Foundation Announces Development of Comprehensive Biomarker Observatoryhttps://practicalneurology.com/news/alzheimers-drug-discovery-foundation-announces-development-of-comprehensive-biomarker-observatory/2470602/The Alzheimer’s Drug Discovery Foundation (ADDF; New York, NY) announced the investment of $3.2 million to the University of Nevada Las Vegas (UNLV) to develop the first ever Biomarker Observatory for Alzheimer disease (AD). The Biomarker Observatory is designed to record and categorize inf
- FDA Greenlights First Treatment for Niemann-Pick Disease Type Chttps://practicalneurology.com/news/fda-greenlights-first-treatment-for-niemann-pick-disease-type-c/2470589/The Food and Drug Administration (FDA) has approved Miplyffa (arimoclomol; Zevra Therapeutics, Celebration, FL) for use in combination with miglustat for the treatment of neurologic manifestations of Niemann-Pick disease type C (NPC) for adult and pediatric patients aged ≥2 years. Miplyffa is
- McDonald Criteria Updates for MS Diagnosis Announcedhttps://practicalneurology.com/news/mcdonald-criteria-updates-for-ms-diagnosis-announced/2470587/Proposed revisions to the 2017 McDonald diagnostic criteria for multiple sclerosis (MS) were announced at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The updates, which will be published later this year, provide guidance on the use of im
- Long-Term Data Reveal Ocrevus Comparable to Tysabri Tx in Effectiveness, Safety Outcomeshttps://practicalneurology.com/news/long-term-data-reveals-ocrevus-comparable-to-tysabri-tx-in-effectiveness-safety-outcomes/2470583/Treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) for people with multiple sclerosis (MS) showed comparable effectiveness, safety, and treatment persistence to treatment with Tysabri (natalizumab; Biogen, Cambridge, MA) over a 5-year observation period. The results of a lon
- Promising Results for mAb Migraine Treatment Targeting PACAP Reported in NEJMhttps://practicalneurology.com/news/promising-results-for-mab-migraine-treatment-targeting-pacap-reported-in-nejm/2470582/A single intravenous infusion of Lu AG09222 (Lundbeck, Deerfield, IL), a humanized monoclonal antibody (mAb) that targets the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand, was found to be superior to placebo in reducing migraine frequency over 4 weeks. The results of a phase
- Wearable Chest Sleep Apnea Test Receives FDA Clearancehttps://practicalneurology.com/news/wearable-chest-sleep-apnea-test-receives-fda-clearance/2470557/The Food and Drug Administration (FDA) has granted 510(k) clearance to SANSA (Huxley Medical, Atlanta, GA), a sleep apnea patch that is worn on the chest. SANSA is an at-home, single-point-of-contact diagnostic device that does not require additional attachments such as belts, wires, or hoses. Th
- Intranasal Foralumab Receives Fast Track Designation as Potential Tx for Non-Active SPMShttps://practicalneurology.com/news/intranasal-foralumab-receives-fast-track-designation-as-potential-tx-for-non-active-spms/2470554/An intranasal formulation for foralumab (Tiziana Life Sciences, New York, NY) has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Foralumab is a fully human
- Once-Daily Pill Approved to Treat Forms of Astrocytoma and Oligodendrogliomahttps://practicalneurology.com/news/once-daily-pill-approved-to-treat-forms-of-astrocytoma-and-oligodendroglioma/2470553/The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib; Servier, Boston, MA) for the treatment of adults and children aged ≥12 years with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutati
- Promising Results for Novel Sigma-1 Receptor Therapy as Alzheimer Treatmenthttps://practicalneurology.com/news/novel-sigma-1-receptor-therapy-slowed-clinical-progression-in-alzheimer-disease/2470543/Treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) for people with early Alzheimer disease (AD) was associated with slowed clinical progression in cognitive and functional outcomes. Anavex2-73 is a small-molecule activator of the sigma-1 receptor (SIGMAR1) that is orally